The proposed transaction would strengthen Richter’s commercial presence in the United States, including in women’s health.
Under a scheme implementation deed announced Monday, Richter would acquire all Mayne Pharma shares for AUD 6.40 each.
The acquisition requires regulatory and shareholder approval and is conditional on the completion of Mayne Pharma’s sale of its international business segment to Evaris Pharma. Mayne Pharma’s board has recommended that shareholders vote in favor of the deal.
“Mayne’s existing portfolio – including our estetrol-based innovative combination contraceptive pill – and its commercial footprint provide a strong base to build on and will allow us to bring new treatments to millions of women in the United States across several therapeutic segments, where there is significant unmet medical need,” said László Kovács, Richter’s deputy CEO.
Mayne Pharma CEO Aaron Gray said the company had strengthened its position in the U.S. market while broadening patient access.
“We have established Mayne Pharma as a leader in Women’s Health and Dermatology in the United States, with expanded patient access through the DistributeRx platform launch in March 2026,” Gray said.
“More recently with the agreed divestment of the International business to Evaris Pharma, we are simplifying the Company around a single market focus within the United States. The offer from Richter recognizes the value of that work,” he added.



